Repros Therapeutics (RPRX) Tops Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Repros Therapeutics Inc.(R) Reports Third Quarter 2014 Financial Results
November 10, 2014 9:03 AM ESTTHE WOODLANDS, Texas, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced financial results for the third quarter ended September 30, 2014.
Financial Results
Net loss for the three month period ended September 30, 2014, was ($7.4) million or ($0.32) per share as compared to a net loss of ($6.0) million or ($0.26) per share for the same period in 2013. The net loss for the nine month period ended September 30, 2014, was ($24.6) million or ($1.06) per share as compared to a net loss of ($20.6) million or ($1.03) per share for the same period in 2013. The increases in net... More
